Investor Type | Firm |
Type of Fund | VC |
Industries | BioTech • FinTech (& Financials services) • CleanTech • A.I. (& Big Data) • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Life Science • Pharmaceutical (& Medicine) |
Stages | Seed, Startup, Early Stage, Expansion, Series A, Series B, Pre-seed |
Investing | United Kingdom • Germany • France • Sweden • Netherlands • Denmark |
Investment Range | $100,000 - $5,000,000 |
Investment Sweet Spot | $1,500,000 |
Assets Under Management | $239,000,000 |
Kurma Partners is a venture capital firm specializing in equity investments, with a focus on sectors including life science, biotechnology, healthcare, medical science, nutrition, and environmental science. Founded in 2009 and headquartered in Paris, France, the firm plays a significant role in the healthcare and biotechnology funding landscape in Europe. They target various stages of company maturity, from seed and startup phases to early stage, expansion, series A, and series B investment rounds, with a special interest in nurturing high-potential companies from inception to capital expansion. Their investment amounts range from a minimum of €100,000 to a maximum of €5,000,000, with a preferred 'sweet spot' of €1,500,000. Managing assets under the sum of €870 million, Kurma Partners has financed 66 companies and founded 24 since their inception. They boast having strong networks with European academic research organizations, supporting the development of disruptive scientific discoveries into innovative medicines and medical devices for diseases with high unmet medical needs. Additionally, they are dedicated to sustainable development, adhering to ESG practices. Kurma Partners supports the health and wellness of communities by aligning their missions with the United Nations Sustainable Development Goal No. 3. Furthermore, they actively engage in an ESG approach, having developed a charter, joined the UN PRI in June 2021, and committed to developing an Ethics Charter for their portfolio companies while promoting best ESG practices and collecting extra-financial data on all their portfolio companies. Their investments are also supported by InnovFin Equity, backed by the European Union's Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI), which is part of the Investment Plan for Europe.